SGLT2抑制剂在糖尿病肾病治疗中的研究进展

发布时间：2018-06-02 20:48

本文选题：SGLT2抑制剂 + 糖尿病肾病　；参考：《南昌大学》2017年硕士论文

【摘要】：背景:糖尿病肾病(Diabetic kidney disease,DKD)是糖尿病的主要并发症之一,它更是发达国家引起终末期肾脏病(End-stage renal disease,ESRD)最常见的病因。钠-葡萄糖协同转运蛋白2(Sodium glucose co-transporter 2,SGLT2)抑制剂,因其自身独特的机制特点而受到越来越多的关注,尤其是在糖尿病肾病治疗中的肾脏保护作用,相关的研究越来越多。目的:通过综述目前SGLT2抑制剂在DKD研究和治疗方面的进展,为DKD的临床治疗提供一些参考。方法:用计算机检索中国知网、万方、PubMed等数据库,筛选关于SGLT2抑制剂治疗DKD的相关研究的文献。结果:检索出多篇关于SGLT2抑制剂治疗DKD的相关研究的文献,通过阅读文献及查阅资料,归纳总结出SGLT2抑制剂治疗DKD的研究进展。结论:SGLT2抑制剂可独立于胰岛素之外强化对血糖的控制,还可使体重减轻,使血压和尿酸降低等,此外,它更有改善肾脏血流动力学的作用,可减少肾小球超滤和肾小球内压,使尿蛋白降低,对提高DKD的疗效和预后有益。但目前有部分研究亦显示,长期使用SGLT2抑制剂也有一定潜在风险。因此,对于SGLT2抑制剂的肾脏保护机制和潜在风险,还需更多多中心、大样本的基础研究和临床数据观察,为更科学和合理的使用SGLT2抑制剂提供更多循证医学依据。
[Abstract]:Background: diabetic kidney disease (DKD) is one of the main complications of diabetes mellitus, and it is the most common cause of End-stage renal disease (ESRD) in developed countries. Sodium glucose co-transporter 2(Sodium glucose co-transporter 2 SGLT2 inhibitor has attracted more and more attention due to its unique mechanism, especially its renal protection in the treatment of diabetic nephropathy. Objective: to provide some references for the clinical treatment of SGLT2 by reviewing the recent advances in the research and treatment of DKD. Methods: to search the databases of SGLT2 inhibitor and SGLT2 inhibitor for the treatment of DKD by computer. Results: several literatures on the treatment of DKD with SGLT2 inhibitors were retrieved, and the research progress of SGLT2 inhibitors in the treatment of DKD was summarized by reading the literature and consulting data. ConclusionsSGLT2 inhibitor can enhance blood glucose control independently of insulin, reduce body weight, blood pressure and uric acid, etc. In addition, it can improve renal hemodynamics and reduce glomerular ultrafiltration and intraglomerular pressure. It is beneficial to improve the curative effect and prognosis of DKD by lowering urinary protein. However, some studies also show that long-term use of SGLT2 inhibitors also has some potential risks. Therefore, more centers are needed for the renal protection mechanism and potential risks of SGLT2 inhibitors, and large samples of basic research and clinical data observation are needed to provide more evidence based medical evidence for more scientific and rational use of SGLT2 inhibitors.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R587.2;R692.9

【相似文献】